Zimmer Biomet Holdings Inc (ZBH, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Zimmer Biomet Holdings Inc is a medical device company. It designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery under brands like NexGen, Persona, Zimmer, and Polaris. Zimmer Biomet Holdings Inc has a market cap of $32.37 billion; its shares were traded at around $157.40 with a P/E ratio of 28.78 and P/S ratio of 4.08. The dividend yield of Zimmer Biomet Holdings Inc stocks is 0.62%. Zimmer Biomet Holdings Inc had annual average EBITDA growth of 1.70% over the past ten years. GuruFocus rated Zimmer Biomet Holdings Inc the business predictability rank of 2.5-star. GuruFocus has detected 2 severe warning signs with Zimmer Biomet Holdings Inc. .
For the last quarter Zimmer Biomet Holdings Inc reported a revenue of $2.1 billion, compared with the revenue of $2.1 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $8 billion, an increase of 0.6% from last year. For the complete 30-year financial data, please go here.. For the last five years Zimmer Biomet Holdings Inc had an average revenue growth rate of 10.6% a year.
The reported diluted earnings per share was $5.47 for the year, an increase of -394.1% from previous year. The Zimmer Biomet Holdings Inc had a decent operating margin of 15.91%, compared with the operating margin of 14.46% a year before. The 10-year historical median operating margin of Zimmer Biomet Holdings Inc is 21.54%. The profitability rank of the company is 8 (out of 10).
At the end of the fiscal year, Zimmer Biomet Holdings Inc has the cash and cash equivalents of $617.9 million, compared with $542.8 million in the previous year. The long term debt was $6.7 billion, compared with $8.4 billion in the previous year. The interest coverage to the debt is 5.6. Zimmer Biomet Holdings Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $157.40, Zimmer Biomet Holdings Inc is traded at 33.2% premium to its historical median P/S valuation band of $118.16. The P/S ratio of the stock is 4.08, while the historical median P/S ratio is 3.06. The intrinsic value of the stock is $58.54 a share, according to GuruFocus DCF Calculator. The stock gained 28.53% during the past 12 months.
For the complete 20-year historical financial data of ZBH, click here.
